Novo Holdings A/S is pleased to announce the appointment of Britt Meelby Jensen, CEO of Atos Medical, as a new member of the Novo Advisory Group.
The appointment of Britt Meelby Jensen further strengthens the competencies of the Novo Advisory Group as Novo Holdings continues to increase its life science investments in the future.
Kasim Kutay, CEO of Novo Holdings, says: “We are delighted that Britt Meelby Jensen is joining the Novo Advisory Group. Britt is a highly respected business leader with a broad background within life sciences, including pharma, diagnostics, biotech and MedTech. Her knowledge and experience will provide the advisory group with valuable insights into priority sectors for Novo Holdings.”
Britt Meelby Jensen has served as CEO of Atos Medical since 2019 after serving as CEO of Zealand Pharma A/S and Dako A/S previously. Furthermore, she has in-depth knowledge and understanding of the Novo Group having held various leadership positions between 2002-2013 at Novo Nordisk A/S.
Britt Meelby Jensen says: “I am very pleased to be joining the Novo Advisory Group. Novo Holdings has an impressive track record and I am delighted to be part of such an ambitious group. I look forward to using my experience from different sectors within the life sciences to help Novo Holdings further increase its investments to the benefit of the Novo Nordisk Foundation.”
About Britt Meelby Jensen
2019– Chief Executive Officer, Atos Medical AB
2015–2019 President and CEO, Zealand Pharma A/S
2013–2014 CEO, Dako A/S (VP and General Manager, Agilent Inc.)
2002–2013 Various leadership positions at Novo Nordisk A/S
2000–2002 McKinsey & Company, Management Consultant
She serves on the boards of Ambu A/S and The Hempel Foundation.
2000 Master of Science (cand.merc.) International Marketing and Management, Copenhagen Business School
1998 MBA, Solvay Business School, ULB, Brussels.